Olutasidenib (FT-2102) - 98%, high purity , Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor, CAS No.1887014-12-1, Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor

Item Number
O414289
Grouped product items
SKUSizeAvailabilityPrice Qty
O414289-5mg
5mg
In stock
$206.90
O414289-10mg
10mg
In stock
$335.90
O414289-25mg
25mg
In stock
$612.90
O414289-50mg
50mg
In stock
$939.90
O414289-100mg
100mg
In stock
$1,484.90

Dehydrogenase Inhibitors

Basic Description

SynonymsD87221 | 0T4IMT8S5Z | FT-2102FT-2102 | AC-36556 | UNII-0T4IMT8S5Z | 5-[[(1S)-1-(6-Chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl]amino]-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile | MFCD00211233 | 2-Pyridinecarbonitrile, 5-(((1S)-1-(6-chloro-1,2-dihydr
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsOlutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H, IDH1-R132C, respectively.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionIsocitrate dehydrogenase [NADP] cytoplasmic inhibitor
Product Description

Information

Olutasidenib (FT-2102) Olutasidenib is a potent, orally bioavailable, brain penetrant and selective mutant IDH1 (mIDH1) inhibitor with IC50 of 21.1 nM, 114 nM for IDH1-R132H , IDH1-R132C , respectively.


Targets

IDH1 (R132H) (Cell-free assay); IDH1 (R132C) (Cell-free assay) 21.1 nM; 114 nM


In vitro

Profiling in various mIDH1 over-expressing U87 cells and HCT116 cells reveals that olutasidenib potently inhibits 2-HG production by multiple IDH1-R132 mutants (R132H, R132C, R132G, R132L), suggesting olutasidenib could be efficacious against most IDH1-R132 mutant-expressing tumors. Olutasidenib is highly selective for IDH1 isoforms, showing no appreciable inhibition against wild-type IDH1 and IDH2 mutants..


In vivo

In IDH1-R132H/ xenograft models, the free concentration of Olutasidenib is comparable in plasma and xenograft tumors, and exposures are dose-dependent. In comparison to the vehicle treated group, Olutasidenib shows a time and dose-dependent inhibition of 2-HG levels in tumor. Calculations based upon the percentage of suppression of 2-HG concentration in tumor versus the free drug concentration in tumor give in vivo IC50 values of 26 nM and 36 nM in the HCT116-IDH1-R132H or HCT116-IDH1-R132C models, respectively. Olutasidenib has good cell permeability and low efflux ratio in the male CD-1 mouse, which indicate a low probability of p-glycoprotein driven efflux..


Cell Research(from reference)

Cell lines:HCT116-IDH1-R132H/+, HCT116-IDH1-R132C/+, HT1080, U87MG cells 

Incubation Time:24 h 

Product Properties

ALogP1.234
HBD Count2
Rotatable Bond3

Associated Targets(Human)

IDH1 Tclin Isocitrate dehydrogenase [NADP] cytoplasmic (9 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
IDH1 Tclin Isocitrate dehydrogenase [NADP] cytoplasmic (40980 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name 5-[[(1S)-1-(6-chloro-2-oxo-1H-quinolin-3-yl)ethyl]amino]-1-methyl-6-oxopyridine-2-carbonitrile
INCHI InChI=1S/C18H15ClN4O2/c1-10(21-16-6-4-13(9-20)23(2)18(16)25)14-8-11-7-12(19)3-5-15(11)22-17(14)24/h3-8,10,21H,1-2H3,(H,22,24)/t10-/m0/s1
InChi Key NEQYWYXGTJDAKR-JTQLQIEISA-N
Canonical SMILES CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N
Isomeric SMILES C[C@@H](C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N
PubChem CID 118955396
Molecular Weight 354.79

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

6 results found

Lot NumberCertificate TypeDateItem
I2208118Certificate of AnalysisJul 04, 2022 O414289
I2208119Certificate of AnalysisJul 04, 2022 O414289
I2208120Certificate of AnalysisJul 04, 2022 O414289
I2208121Certificate of AnalysisJul 04, 2022 O414289
I2208122Certificate of AnalysisJul 04, 2022 O414289
L2412241Certificate of AnalysisJul 04, 2022 O414289

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 71 mg/mL (200.11 mM); Water: Insoluble; Ethanol: Insoluble;
DMSO(mg / mL) Max Solubility71
DMSO(mM) Max Solubility200.118379886694
Water(mg / mL) Max Solubility<1

Related Documents

References

1. Wang G, Sai K, Gong F, Yang Q, Chen F, Lin J.  (2014)  Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner..  Mol Med Rep,  (5): (1799-805).  [PMID:24626950] [10.1021/op500134e]
2. Caravella JA, Lin J, Diebold RB, Campbell AM, Ericsson A, Gustafson G, Wang Z, Castro J, Clarke A, Gotur D et al..  (2020)  Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor..  J Med Chem,  63  (4): (1612-1623).  [PMID:31971798] [10.1021/op500134e]

Solution Calculators